Search

Your search keyword '"ILEAL conduit surgery"' showing total 88 results

Search Constraints

Start Over You searched for: Descriptor "ILEAL conduit surgery" Remove constraint Descriptor: "ILEAL conduit surgery" Publisher wolters kluwer uk Remove constraint Publisher: wolters kluwer uk
88 results on '"ILEAL conduit surgery"'

Search Results

1. EDITORIAL COMMENTS.

2. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.

3. Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy.

4. Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility.

5. National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy.

6. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic.

7. Obesity and Complication Risk From Radical Cystectomy: Identifying a Body Mass Index Threshold.

8. REPLY BY AUTHORS.

9. Untitled.

10. PD63-08 THE ASSOCIATION BETWEEN DURATION OF ANTIBIOTICS AND INFECTIOUS COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY: ANALYSIS OF THE 2019-2021 NSQIP DATABASE.

11. MP71-17 10-YEAR TRENDS IN PERIOPERATIVE OUTCOMES IN BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH ILEAL CONDUIT URINARY DIVERSION.

13. MP77-05 POST-OPERATIVE AND FUNCTIONAL OUTCOMES COMPARISON BETWEEN PATIENTS UNDERGOING STENT VERSUS STENTLESS ROBOT-ASSISTED RADICAL CYSTECTOMY WITH ORTHOTOPIC NEOBLADDER.

14. MP77-02 IMPACT OF DIABETES MELLITUS ON ONCOLOGIC OUTCOMES IN PATIENTS RECEIVING ROBOT-ASSISTED RADICAL CYSTECTOMY FOR BLADDER CANCER.

15. MP77-01 LONGITUDINAL ASSESSMENT OF PERIOPERATIVE, POSTOPERATIVE AND EARLY HEALTH RELATED QUALITY OF LIFE OUTCOMES: HEAD TO HEAD COMPARISON BETWEEN ILEAL CONDUIT AND PADUA ILEAL NEOBLADDER FROM A SINGLE CENTER RANDOMISED CONTROLLED TRIAL.

16. MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL.

20. MP53-02 RISK OF NODE METASTASES IN MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMO- OR IMMUNOTHERAPY AND RADICAL CYSTECTOMY WITH BILATERAL PELVIC LYMPH NODE DISSECTION.

22. PD38-06 EFFECT OF MAXIMAL TRANSURETHRAL RESECTION PRIOR TO NEOADJUVANT CHEMOTHERAPY ON ONCOLOGICAL OUTCOMES IN PATIENTS WHO UNDERGO RADICAL CYSTECTOMY: A MULTICENTER RETROSPECTIVE STUDY.

23. PD38-05 DELINEATING THE INTERPLAY OF CUMULATIVE 90-DAY MORBIDITY AND HEALTH-RELATED QUALITY OF LIFE AFTER RADICAL CYSTECTOMY—PROSPECTIVE EVIDENCE FROM THE COMPACT REGISTRY.

24. PD36-04 REMOTE DIGITAL SURVEILLANCE AND MACHINE LEARNING MODELLING TO PREDICT SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER—A SECONDARY OUTCOME ANALYSIS OF THE IROC TRIAL.

26. MP47-08 IMPACT OF HYPOGONADISM ON RADICAL CYSTECTOMY OUTCOMES.

27. PD34-08 A PROSPECTIVE RANDOMIZED PHASE 3 TRIAL EVALUATING BENEFITS OF PERISTOMAL MESH PLACEMENT AT THE TIME OF RADICAL CYSTECTOMY AND ILEAL CONDUIT FORMATION.

28. PD34-07 LONG-TERM ONCOLOGIC OUTCOMES OF TETRAMODAL BLADDER-PRESERVATION THERAPY INCORPORATING INDUCTION CHEMORADIOTHERAPY AND CONSOLIDATIVE PARTIAL CYSTECTOMY WITH PELVIC LYMPHNODE DISSECTION FOR MUSCLE-INVASIVE BLADDER CANCER.

29. PD34-06 CHANGES IN BODY COMPOSITION FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY.

30. PD34-04 DECISION REGRET IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A MULTICENTER ANALYSIS.

31. MP38-20 RISK OF UPPER URINARY TRACT DISSEMINATION IN cT3 BLADDER CANCER PATIENTS TREATED WITH DOUBLE-J STENT VERSUS NEPHROSTOMY TUBE PRIOR TO RADICAL CYSTECTOMY.

32. V08-12 HOME TELEMONITORING OF PATIENTS UNDERGOING RADICAL CYSTECTOMY USING TYTOCARE DEVICE: COMPARATIVE ANALYSIS OF EARLY POST-OPERATIVE OUTCOMES.

34. MP34-19 ROLE OF SELF-ASSESSED SOCIAL SUPPORT AND SOCIAL DEPRIVATION INDEX IN PREDICTING COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY.

37. MP22-02 PATHOLOGIC AND SURVIVAL OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR "PROGRESSIVE" AND "DE NOVO" MUSCLE-INVASIVE BLADDER CANCER: A META-ANALYSIS STRATIFIED BY NEOADJUVANT CHEMOTHERAPY STATUS.

45. MP22-18 BODY MORPHOMETRY ANALYSIS CAN IDENTIFY PATIENTS AT RISK OF PARASTOMAL HERNIA FOLLOWING RADICAL CYSTECTOMY WITH ILEAL CONDUIT.

46. MP22-15 THE USE OF PERIOPERATIVE OPIOIDS IS ONCOLOGICALLY SAFE IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER.

48. MP22-13 FRAILTY ADAPTED ERAS PATHWAY FOR PATIENTS WITH BLADDER CANCER REQUIRING SURGERY: THE GLOBAL RADICAL CYSTECTOMY EVALUATION AND MANAGEMENT (GRACEM) STUDY PROTOCOL.

Catalog

Books, media, physical & digital resources